Treatment of patients with AATD involves AAT augmentation therapy, which can aid in modulating this uncontrolled complement cascade by disrupting C3 activation and significantly reducing C3d plasma levels when compared with those not on therapy [16]. Here, C3 is linked to alpha 1-antitrypsin deficiency.